Contact Us
Contact Us
Contact Us


Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage drug assets, principally in the cancer field.

Read More


Bisantrene is a cancer drug that is related to the anthracyclines, the most widely used class of chemotherapy drugs.

Read More

Board & Management

Find out more about Race Oncology’s board of directors and management team.

Read More

Rediscovering Bisantrene

Race's first important asset is a chemotherapy drug called Bisantrene which was the subject of more than 40 phase II clinical studies before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology has rediscovered Bisantrene and we plan to put this valuable drug back in the hands of clinicians to treat Leukaemia.
In the United States, Race owns two granted patents on Bisantrene and has secured Orphan Drug designation and Rare Paediatric Disease designation. Our goal is to complete clinical development and gain approval by the US FDA.
Click to Play Video

Race Oncology CEO Peter Molloy and Chair Dr Bill Garner.

Featured On

In The News

Business News Australia
The West Australian
ABC News
Sydney Morning Herald
Money News with Ross Greenwood

Latest News

Read All Stories

Race Oncology

© 2019 Race Oncology. Website By Multiplier